Clinical Trial

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-09-30; most recent amendment 2026-04-02.
Status change: Not Yet Recruiting → Recruiting 2025-11-28
Trial Details
NCT Number NCT07211542
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Moderate-to-severe Atopic Dermatitis
Enrollment 75 participants
Start Date 2025-11-07
Primary Completion 2026-09 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-04-08